Blackstone Inc. (BX) is a publicly traded Financial Services sector company. As of November 15, 2026, BX trades at $120.19 with a market cap of $95.03B and a P/E ratio of 25.14. BX moved +0.46% today. Year to date, BX is -25.97%; over the trailing twelve months it is -13.86%. Its 52-week range spans $101.73 to $190.09. Analyst consensus is buy with an average price target of $137.50. Rallies surfaces BX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Blackstone’s Pfizer funding backs berobenatide development, with 10 Phase 3 trials planned or underway: Blackstone will provide Pfizer up to $1.5 billion through 2028 to help develop berobenatide, an experimental monthly obesity treatment. Pfizer says it has 10 ongoing and planned Phase 3 trials; Blackstone’s milestone payments depend on U.S. regulatory approval and certain commercial sales milestones.
| Metric | Value |
|---|---|
| Price | $120.19 |
| Market Cap | $95.03B |
| P/E Ratio | 25.14 |
| EPS | $4.47 |
| Dividend Yield | 1.12% |
| 52-Week High | $190.09 |
| 52-Week Low | $101.73 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.11B |
| Net Income | $6.83B |
| Gross Margin | 0.00% |
16 analysts cover BX: 0 strong buy, 9 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $137.50.